Edwards Lifesciences Corp.

Company Overview

Edwards Lifesciences Corp. offers medical technologies for the treatment of critical conditions, vascular diseases, and structural heart disorders. The company specializes in the development of advanced heart valve systems used in both surgical and transcatheter procedures for heart valve replacement and repair. It also offers a range of surgical heart valve and repair solutions, along with minimally invasive hemodynamic monitoring systems, pressure-monitoring devices, hemofiltration technologies, and vascular stents.

The company’s transcatheter and surgical heart valve therapy products are manufactured in the U.S. Singapore and Switzerland. Its critical care products are manufactured in its facilities in Puerto Rico and the Dominican Republic.

Financial Highlights (FY 2025)

Company's Business Segments

• Transcatheter Aortic Valve Replacement : Transcatheter heart valve replacement technologies are designed for the minimally invasive replacement of Aortic heart valves.
• Transcatheter Mitral and Tricuspid Therapies : The development of transcatheter heart valve repair and replacement technologies designed to treat Mitral, Tricuspid valve diseases.
• Surgical Structural Heart : This segment includes innovations for cardiac surgery patients, products like RESILIA tissue, INSPIRIS RESILIA aortic valve, KONECT RESILIA which has VFit technology first pre-assembled, ready-to-implant, tissue valved conduit for complex combined procedures.
• Critical Care : This segment includes advanced Hemodynamic monitoring systems used to measure a patient's heart function and fluid status in surgical and intensive care settings. Edwards’ complete hemodynamic portfolio helps clinicians make proactive clinical decisions that can improve patient recovery. The portfolio includes the minimally-invasive FloTrac and Acumen IQ sensors, the noninvasive ClearSight, Acumen IQ cuffs, and the ForeSight noninvasive tissue oximetry sensor.